Panvac-v (** Panvac-V (investigational - no approved commercial brands available) **)

Description

Panvac-V is an investigational vaccine being studied for certain types of advanced cancer, including colorectal cancer. It is designed to stimulate the body's immune system to target cancer cells. This vaccine uses a modified vaccinia virus (a type of pox virus) to deliver genetic material related to two proteins often found on cancer cells: carcinoembryonic antigen (CEA) and mucin-1 (MUC-1). The vaccine also includes genes for molecules that help activate immune cells. It is given in combination with another vaccine, Panvac-F, and a drug called sargramostim. Clinical trials are primarily focused on evaluating the safety and potential effectiveness of this vaccine approach in patients with advanced cancers that express CEA or MUC-1. It is important to note that Panvac-V is still in early stages of development and is not yet approved for use in colorectal cancer or any other cancer.

Mechanism of Action

Panvac-V is a vaccine designed to boost the immune system's response against cancer cells. It uses a modified vaccinia virus (pox virus) as a delivery system. This virus carries genes encoding CEA and MUC-1, which are proteins often found in high amounts on the surface of certain cancer cells, including some colorectal cancers. The vaccine also contains genes for costimulatory molecules (B7-1, ICAM-1, LFA-3) that help activate immune cells, specifically T-cells. By introducing these genes into the body, the vaccine aims to train the immune system to recognize and attack cancer cells expressing CEA and MUC-1. The specific mechanism involves the virus infecting cells and causing them to produce CEA, MUC-1, and costimulatory molecules, which then trigger an immune response.

Side Effects

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials